Stopped: The Imiquimod 3.75% was ineffective
The aim of this research project is to design a new model of human itch by application of Zyclara cream. Further, the aim is to characterize the model and to verify if the mechanism of action of imiquimod follows the histaminergic or non-histaminergic pathway by using the anti-histamine drug doxepin. The last goal is to evaluate the interaction between the activation of TLR7 receptor and the activation of TRPA1 and TRPM8 receptors, which are two of the most important receptors involved in the transduction of noxious stimuli, and to evaluate to which extent these three channel populations functionally overlap.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Superficial blood perfusion by by a Speckle contrast imager (FLPI, Moor Instruments, England).
Timeframe: Change from baseline, to maximum 19 days after intervention
Trans-epidermal Water Loss (TEWL)
Timeframe: Change from baseline, to maximum 19 days after intervention
Neurogenic Inflammatory Response and Pigmentation
Timeframe: Change from baseline, to maximum 19 days after intervention
Measuring Alloknesis
Timeframe: Change from baseline, to maximum 19 days after intervention
Thermal measurements (cold and warm detection thresholds, cold and heat pain thresholds)
Timeframe: Change from baseline, to maximum 19 days after intervention
Measurement of Pain to Supra-threshold Heat Stimuli
Timeframe: Change from baseline, to maximum 19 days after intervention
Measurement of Mechanical Detection Thresholds, Mechanical Pain Threshold and sensitivity
Timeframe: Change from baseline, to maximum 19 days after intervention